The recommendation appears on page 26 of the report.
In its first opinion made public on Monday, the new Committee for monitoring and anticipating health risks (Covars), successor to the Scientific Council, recommends “quickly carrying out studies on the comparative real-life effectiveness of bivalent vaccines”.
These target both the original virus strain and the Omicron variant (either its BA.1 sublineage or BA.4 and BA.5).
Arrived gradually in France since the end of September, they must be used as a priority.
But it is still impossible to know what gain in effectiveness they really bring compared to the original vaccines.
Subscribe to read more
Already subscribed?
To log in
